关键词：良性前列腺增生症；非癌性增殖；衰老；激素失衡；异常细胞
摘 要：Benign prostatic hyperplasia is a condition characterized by noncancerous proliferation of prostate gland cells. This causes the gland to enlarge and, as a result, press against the urethra, constricting urine flow. It is associated with aging, hormone imbalances, and abnormal cell growth. Benign prostatic hyperplasia devices are used to perform invasive and MI surgeries to remedy a blocked urethra.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market overview

03.2 Product offerings

04. Market Research Methodology

04.1 Market research process

04.2 Research methodology

05. Introduction

06. Market Landscape

06.1 Market overview

06.2 Market size and forecast

06.3 Five forces analysis

07. Benign Prostatic Hyperplasia: An Overview

07.1 Incidence and prevalence

07.2 Major symptoms

08. Market Segmentation by Procedure

08.1 TURP

08.2 Laser surgery

08.3 TUMT

08.4 TUNA

08.5 Prostatic stenting

08.6 Others

09. Geographical Segmentation

09.1 Benign prostatic hyperplasia devices market in

Americas

09.1.1 Market size and forecast

09.2 Benign prostatic hyperplasia devices market in

EMEA

09.2.1 Market size and forecast

09.3 Benign prostatic hyperplasia devices market in

APAC

09.3.1 Market size and forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and Their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and Their Impact

17. Vendor Landscape

17.1 Competitive scenario

17.1.1 Key news

17.2 Vendor analysis 2014

17.3 Other prominent vendors

18. Key Vendor Analysis

18.1 Endo International

18.1.1 Key facts

18.1.2 Business overview

18.1.3 Business segmentation by revenue 2013

18.1.4 Business segmentation by revenue 2012 and 2013

18.1.5 Geographical segmentation by revenue 2013

18.1.6 Business strategy

18.1.7 Recent developments

18.1.8 SWOT analysis

18.2 Karl Storz

18.2.1 Key facts

18.2.2 Business overview

18.2.3 Business segmentation

18.2.4 Business strategy

18.2.5 Key developments

18.2.6 SWOT analysis

18.3 Lumenis

18.3.1 Key facts

18.3.2 Business overview

18.3.3 Business segmentation by revenue 2013

18.3.4 Business segmentation by revenue 2012 and 2013

18.3.5 Geographical segmentation by revenue 2013

18.3.6 Business strategy

18.3.7 Recent developments

18.3.8 SWOT analysis

18.4 Olympus

18.4.1 Key facts

18.4.2 Business overview

18.4.3 Business segmentation by revenue 2013

18.4.4 Sales by geography

18.4.5 Business strategy

18.4.6 Key developments

18.4.7 SWOT analysis

18.5 Urologix

18.5.1 Key facts

18.5.2 Business overview

18.5.3 Business strategy

18.5.4 SWOT analysis

19. Other Reports in This Series